Researchers may have found ways to make a vaccine against all strains of the flu virus, potentially saving millions of lives.
Last year’s flu vaccine rarely works on this year’s strain due to the virus’ very high mutation rate. Worldwide, the seasonal flu virus causes 3 to 5 million cases of severe illness and a further 250 000 to 500 000 deaths every year.
A pandemic flu strain could kill millions in the months it would take scientists to make a specific vaccine.
Three separate EU-funded projects are now developing techniques to teach our immune systems to recognise any flu strain, removing the need for scientists to develop new vaccines each time a new strain appears.
The four-year EDUFLUVAC project is planning to produce a universal flu vaccine suitable for clinical trials by the time it finishes in 2017. While current flu vaccines use one component from the H1, H3, and B flu virus strains, the EDUFLUVAC project will use multiple components from each strain, in order to teach the immune system about the similarities between different strains, producing a broader immune response.
Dr Ed Remarque, an immunologist at the Biomedical Primate Research Centre in the Netherlands, compares it to teaching children what a car is. ‘You show them many different versions of a car to learn what a car is,’ he said. ‘If you show them only one car, they may believe that all cars are red.’
It means that if the immune system sees many strains of flu, it can focus on the similarities and ignore the differences, allowing it to eventually recognise strains it has not yet seen.
This approach was inspired by Dr Remarque’s previous work on developing a malaria vaccine, but the idea of exposing the immune system to multiple strains of the same virus was first suggested by Davenport and Hennessey in the United States in 1957. ‘We are now 57 years down the line and Davenport’s paper from 1957 is really up to date,’ Dr Remarque said.
The goal of the project is to have a universal flu vaccine that would ‘at least provide five years of coverage,’ though problems such as waning immune responses over time may reduce the period of effectiveness.
The vaccine will be sold on a non-profit basis in the developing world, a result negotiated by the European Vaccine Initiative, which is supporting the EDUFLUVAC project. In the developed world, it will be specifically targeted towards high-risk groups such as elderly people and school-age children.
The surface proteins the flu virus uses to invade healthy cells are mushroom-shaped. While the ‘heads’ of the proteins are highly susceptible to mutations, the ‘stems’ are less changeable from one generation to the next, giving antibodies a way to target them.
The FLUNIVAC project, which runs until late 2017, is using this knowledge to produce a different type of universal flu vaccine.
‘Maybe we are already covering future virus strains.’
Dr Tim Beaumont, Senior Scientist, Aimm Therapeutics
By producing antibodies that recognise the stems of the flu surface proteins, the vaccine can ‘neutralize a whole bunch of (flu) viruses,’ explained Dr Tim Beaumont, Senior Scientist at Aimm Therapeutics, a private partner on the project.
This type of vaccine may also neutralize viruses that are now present only in birds and not yet in humans. ‘Maybe we are already covering future virus strains,’ he said.
The project has already produced the antibodies required and future work will involve testing the effects of the vaccine. Similar to the EDUFLUVAC project, FLUNIVAC aims to have a universal flu vaccine ready for early stage clinical trials in four years.
When an outbreak strikes, speed is critical. Health workers must act quickly not only to contain and treat an emerging or re-emerging disease, but also to use this window to evaluate potential treatments and vaccines. And the challenge becomes even greater in sub-Saharan Africa when you’re trying to develop new approaches in the face of multiple emerging diseases.
Understanding the progression from the stepping reflex to independent walking could help find new therapies for children with cerebral palsy (CP) – a movement disability caused by brain damage before, during or shortly after birth.
Nature provides people with everything from food and water to timber, textiles, medicinal resources and pollination of crops. Now, a new approach aims to measure exactly what a specific ecosystem supplies in order to incentivise decision-makers and businesses to help combat biodiversity loss.
Europe’s position on privacy, regulation and competition could be a key way to attract entrepreneurs who share those values but there is still some work to do in encouraging ambition, according to Nicklas Bergman, a Swedish entrepreneur and technology investor. Over the past two years, he and other entrepreneurs have advised the European Commission on the design of the European Innovation Council (EIC), an initiative to support companies, researchers and entrepreneurs hoping to start their own business or scale up their projects internationally. The second phase of the pilot was launched on 18 March 2019.
To protect species, we need to speak the language of business, say experts.
He has advised the EU on its new European Innovation Council.
Species loss needs urgent international action, says Prof. Georgina Mace.